



## **PRESS RELEASE**

**September 7<sup>th</sup>, 2006**

---

### **GRAFFINITY AND BOEHRINGER INGELHEIM PHARMACEUTICALS ENTER INTO DRUG DISCOVERY RESEARCH AGREEMENT**

HEIDELBERG, Germany — September 7, 2006 — Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of various novel small molecule hit series against multiple drug targets.

Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify and evolve small molecule hit structures focusing on compounds with novel modes of action.

Financial details of the transaction were not disclosed.

Mathias Woker, Senior Vice President of Business Development of Graffinity, stated, "This collaboration demonstrates again that Graffinity's fragment based drug discovery technology is one of the most important and reliable alternatives to standard approaches of identifying NCEs. When leading companies, such as Boehringer Ingelheim, choose to work with us, they know that they significantly increase their chances of finding truly novel, efficacious and safe small molecules – in particular since they are accessing one of the largest fragment libraries available today with about 20,000 fragments and 90,000 lead-like structures. They also know that, given these strongly improved odds in their favor, they effectively save money and valuable time in drug discovery. Our fragment based drug discovery platform and process are uniquely suited for challenging drug targets, since our drug fragment libraries, together with the proprietary label- and assay-free high-throughput imaging technology, allow us to generate quality hit structures for both known as well as novel modes of action – thus exploiting completely new avenues in chemical diversity space."

#### **About Graffinity Pharmaceuticals GmbH**

Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of fragment based drug discovery. Utilizing its unique technology base, Graffinity is pursuing high-profile

drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. The Company employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinity's proprietary fragment screening platform combines new chemistry approaches, physics, information technology and microsystems technologies to screen drug targets for its clients. Critically important is the combination of chemical microarrays of drug fragment libraries with a proprietary method for the standardized, label-free detection of compound-protein interactions utilizing SPR imaging. Through Graffinity's approach small organic molecules identified in screening efficiently evolve into highly specific lead-like structures in subsequent steps. Graffinity's rapid and scalable drug discovery method explores a rich chemical universe to find the compounds that will be needed to develop drugs against the wealth of targets already available or about to be discovered by genomics. The company has established collaborations with pharmaceutical and biotechnology partners including Pfizer, Eli Lilly, Serono, Genentech, and Novartis. Graffinity's unique fragment based discovery platform has been invented in 1998, and has been in routine industrial use since 2002 in screening more than 50 drug targets.

For more information, please visit [www.graffinity.com](http://www.graffinity.com).

Graffinity Media Contact for Europe:

Dr. Kristina Schmidt  
General Manager  
Graffinity Pharmaceuticals GmbH  
Tel. +49 6221 6510-112  
[kristina.schmidt@graffinity.com](mailto:kristina.schmidt@graffinity.com)

Graffinity Media Contact for the  
Americas and Asia:

Mathias Woker  
Senior Vice President, Business Development  
Graffinity Pharmaceuticals GmbH  
Tel. +1 (401) 301-1086  
[mathias.woker@graffinity.com](mailto:mathias.woker@graffinity.com)

###